FDA Drug Name Guidance Is “Premature” Without More Data, Cmte. Says
Executive Summary
Development of an FDA guidance on how to screen proprietary drug names for potential medication errors would be premature without more outcomes data, the Drug Safety & Risk Management Advisory Committee agreed Dec. 4
You may also be interested in...
Drug Names Will Be Reviewed By FDA Within 90 Days Under PDUFA Timetable
FDA is establishing timetables for review of proprietary drug names as part of the next cycle of the Prescription Drug User Fee Act
Drug Names Will Be Reviewed By FDA Within 90 Days Under PDUFA Timetable
FDA is establishing timetables for review of proprietary drug names as part of the next cycle of the Prescription Drug User Fee Act
FDA Drug Name Guidance Is “Up In The Air,” Agency Tells DIA
FDA may not proceed with a planned guidance for industry on pre-marketing risk assessment of drug names, labeling and packaging, Medical Errors & Technical Support Division Deputy Director Carol Holquist said at the Drug Information Association annual meeting in Washington, D.C. June 16